Similarly, a study based on integrated multi-omics immunotherapy cohorts demonstrated that FAT1 mutations are associated with improved immune checkpoint blockade (ICB) treatment outcomes in both non-small cell lung cancer and melanoma (Zhang et al., 2022). This evidence concerns the gene FAT1 and non-small cell lung carcinoma.